Alzamend Neuro (ALZN) Expected to Announce Quarterly Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) is expected to be issuing its results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last released its earnings results on Tuesday, December 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.53. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Trading Down 3.4%

Shares of NASDAQ ALZN opened at $2.01 on Monday. The company has a market cap of $7.64 million, a price-to-earnings ratio of -0.61 and a beta of -0.25. Alzamend Neuro has a 12 month low of $1.58 and a 12 month high of $10.17. The stock has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $2.24.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alzamend Neuro stock. DRW Securities LLC increased its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 116,319 shares of the company’s stock after buying an additional 25,074 shares during the period. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent quarter. 49.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ALZN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alzamend Neuro in a research report on Monday, December 29th. Ascendiant Capital Markets decreased their target price on shares of Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Alzamend Neuro currently has a consensus rating of “Hold” and a consensus price target of $28.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.